الفهرس 
Standard therapy for chronic hepatitis COnly 14 pages are availabe for public view
 |  | from | 180 |  |  |
| | | from | 180 | | |
Abstract
To maximize the antiviral response, and augment the SVR rates in all CHC patients and particularly non-responders, several new therapeutic approaches are currently under investigation including; NS3protease inhibitors,NS5A, NS5B polymerase inhibitors, cyclophyllin inhibitors, new forms of HCV vaccines, RBV analogues and host-lipid biosynthesis inhibitors. A very promising strategy to overcome viral resistance to current therapy is to anticipate, identify and target the modifiable host factors implicated for antiviral unresponsiveness. Careful evaluation of the patients’ clinical characteristics and previous medical records of non-responders would be of paramount importance to map-out such modifiable risk factors. Insulin resistance, alcohol intake, cigarette smoking and over weight/high BMI come on the top of the list that if effectively corrected, they would give another opportunity to optimize HCV therapy. The widely-used indiscriminate intake of non-approved traditional natural and herbal remedies is not only therapeutically invaluable but also with a substantial hepatotoxicity. Thus, the current use of these non-certified alternative medications should be discouraged by clinicians.